Browse SMC1B

Summary
SymbolSMC1B
Namestructural maintenance of chromosomes 1B
Aliases bK268H5; SMC1L2; SMC1 structural maintenance of chromosomes 1-like 2 (yeast); SMC1BETA; SMC protein 1B; SMC1 ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Chromosome Chromosome, centromere Note=Associates with chromatin. In prophase I stage of meiosis, localizes along the AE of synaptonemal complexes. In late-pachytene-diplotene, the bulk of protein dissociates from the chromosome arms probably because of phosphorylation by PLK, except at centromeres, where cohesin complexes remain. Remains chromatin associated at the centromeres up to metaphase II. At anaphase II, dissociates from centromeres, allowing chromosomes segregation (By similarity).
Domain PF06470 SMC proteins Flexible Hinge Domain
PF02463 RecF/RecN/SMC N terminal domain
Function

Meiosis-specific component of cohesin complex. Required for the maintenance of meiotic cohesion, but not, or only to a minor extent, for its establishment. Contributes to axial element (AE) formation and the organization of chromatin loops along the AE. Plays a key role in synapsis, recombination and chromosome movements. The cohesin complex is required for the cohesion of sister chromatids after DNA replication. The cohesin complex apparently forms a large proteinaceous ring within which sister chromatids can be trapped. At anaphase, the complex is cleaved and dissociates from chromatin, allowing sister chromatids to segregate. The meiosis-specific cohesin complex probably replaces mitosis specific cohesin complex when it dissociates from chromatin during prophase I (By similarity).

> Gene Ontology
 
Biological Process GO:0000819 sister chromatid segregation
GO:0007059 chromosome segregation
GO:0007062 sister chromatid cohesion
GO:0007126 meiotic nuclear division
GO:0051321 meiotic cell cycle
GO:0098813 nuclear chromosome segregation
GO:1903046 meiotic cell cycle process
Molecular Function -
Cellular Component GO:0000775 chromosome, centromeric region
GO:0000793 condensed chromosome
GO:0000794 condensed nuclear chromosome
GO:0000795 synaptonemal complex
GO:0000798 nuclear cohesin complex
GO:0000800 lateral element
GO:0008278 cohesin complex
GO:0030893 meiotic cohesin complex
GO:0034991 nuclear meiotic cohesin complex
GO:0044454 nuclear chromosome part
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG hsa04110 Cell cycle
hsa04114 Oocyte meiosis
Reactome R-HSA-1640170: Cell Cycle
R-HSA-1500620: Meiosis
R-HSA-1221632: Meiotic synapsis
Summary
SymbolSMC1B
Namestructural maintenance of chromosomes 1B
Aliases bK268H5; SMC1L2; SMC1 structural maintenance of chromosomes 1-like 2 (yeast); SMC1BETA; SMC protein 1B; SMC1 ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SMC1B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSMC1B
Namestructural maintenance of chromosomes 1B
Aliases bK268H5; SMC1L2; SMC1 structural maintenance of chromosomes 1-like 2 (yeast); SMC1BETA; SMC protein 1B; SMC1 ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SMC1B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSMC1B
Namestructural maintenance of chromosomes 1B
Aliases bK268H5; SMC1L2; SMC1 structural maintenance of chromosomes 1-like 2 (yeast); SMC1BETA; SMC protein 1B; SMC1 ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SMC1B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1440.633
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.030.958
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2370.577
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.8160.0356
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7160.627
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.9430.606
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4940.453
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9330.322
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.210.835
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1460.739
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2680.669
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.8260.0107
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SMC1B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21171917.61.41
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.427.3-11.90.63
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSMC1B
Namestructural maintenance of chromosomes 1B
Aliases bK268H5; SMC1L2; SMC1 structural maintenance of chromosomes 1-like 2 (yeast); SMC1BETA; SMC protein 1B; SMC1 ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SMC1B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSMC1B
Namestructural maintenance of chromosomes 1B
Aliases bK268H5; SMC1L2; SMC1 structural maintenance of chromosomes 1-like 2 (yeast); SMC1BETA; SMC protein 1B; SMC1 ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SMC1B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SMC1B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSMC1B
Namestructural maintenance of chromosomes 1B
Aliases bK268H5; SMC1L2; SMC1 structural maintenance of chromosomes 1-like 2 (yeast); SMC1BETA; SMC protein 1B; SMC1 ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SMC1B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSMC1B
Namestructural maintenance of chromosomes 1B
Aliases bK268H5; SMC1L2; SMC1 structural maintenance of chromosomes 1-like 2 (yeast); SMC1BETA; SMC protein 1B; SMC1 ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SMC1B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSMC1B
Namestructural maintenance of chromosomes 1B
Aliases bK268H5; SMC1L2; SMC1 structural maintenance of chromosomes 1-like 2 (yeast); SMC1BETA; SMC protein 1B; SMC1 ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SMC1B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSMC1B
Namestructural maintenance of chromosomes 1B
Aliases bK268H5; SMC1L2; SMC1 structural maintenance of chromosomes 1-like 2 (yeast); SMC1BETA; SMC protein 1B; SMC1 ......
Chromosomal Location22q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SMC1B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.